Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Анализ 100 000 геномов опухолей человека раскрывает ландшафт мутационной нагрузки опухоли
2017-04-13
SCID: 54.1/h4p6ue7r
Discuss with AI
PMS2 promoter mutationscomprehensive genomic profilingmicrosatellite instabilitytumor mutational burdenwhole-exome sequencing
Figures from the paper
Abstract (AI)
BACKGROUND: High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown to be more significantly associated with response to PD-1 and PD-L1 blockade immunotherapy than PD-1 or PD-L1 expression, as measured by immunohistochemistry (IHC). The distribution of TMB and the subset of patients with high TMB has not been well characterized in the majority of cancer types. METHODS: In this study, we compare TMB measured by a targeted comprehensive genomic profiling (CGP) assay to TMB measured by exome sequencing and simulate the expected variance in TMB when sequencing less than the whole exome. We then describe the distribution of TMB across a diverse cohort of 100,000 cancer cases and test for association between somatic alterations and TMB in over 100 tumor types. RESULTS: We demonstrate that measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly. We find that a subset of patients exhibits high TMB across almost all types of cancer, including many rare tumor types, and characterize the relationship between high TMB and microsatellite instability status. We find that TMB increases significantly with age, showing a 2.4-fold difference between age 10 and age 90 years. Finally, we investigate the molecular basis of TMB and identify genes and mutations associated with TMB level. We identify a cluster of somatic mutations in the promoter of the gene PMS2, which occur in 10% of skin cancers and are highly associated with increased TMB. CONCLUSIONS: These results show that a CGP assay targeting ~1.1 Mb of coding genome can accurately assess TMB compared with sequencing the whole exome. Using this method, we find that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy. Finally, we identify novel, recurrent promoter mutations in PMS2, which may be another example of regulatory mutations contributing to tumorigenesis.
Key Findings
1
A CGP assay targeting approximately 1.1 Mb of coding genome can accurately assess TMB and identify patients who may benefit from immune checkpoint immunotherapy.
2
A cluster of recurrent PMS2 promoter mutations occurs in 10% of skin cancers and is strongly associated with increased TMB.
3
Across 100,000 cancer cases and over 100 tumor types, a subset of patients has high TMB in nearly every cancer type, including rare tumors.
4
Comprehensive genomic profiling (CGP) TMB measurements strongly reflect whole-exome sequencing results, while variance increases substantially below 0.5 Mb of sequencing territory.
5
TMB increases significantly with age, showing a 2.4-fold difference between patients aged 10 and 90 years.
Research Object
Tumor mutational burden across 100,000 human cancer cases spanning over 100 tumor types
Research Subject
The distribution, measurement variance, age dependence, microsatellite instability relationship, and somatic genetic determinants of tumor mutational burden
Publication Details
Publication Date
2017-04-13
Journal
Publisher
ISSN
Cited by
3593
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data2010
Analysis of protein-coding genetic variation in 60,706 humans2016
The Cancer Genome Atlas Pan-Cancer analysis project2013
Mutational signatures associated with tobacco smoking in human cancer2016